Directive clinique n 422g : Ménopause et ostéoporose.

Objectif: Proposer des stratégies pour améliorer les soins aux femmes en périménopause ou ménopausées d'après les plus récentes données probantes publiées.

Population Cible: Femmes en périménopause ou ménopausées. BéNéFICES, RISQUES ET COûTS: La population cible bénéficiera des plus récentes données scientifiques publiées que leur communiqueront les fournisseurs de soins de santé.

Guideline No. 422g: Menopause and Osteoporosis.

Objective: Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence.

Target Population: Perimenopausal and postmenopausal women.

Benefits, Harms, And Costs: Target population will benefit from the most recent published scientific evidence provided via the information from their health care provider.

Directive clinique n 422f : Ménopause et cancer du sein.

Objectif: Proposer des stratégies pour améliorer les soins aux femmes en périménopause ou ménopausées d'après les plus récentes données probantes publiées.

Population Cible: Femmes en périménopause ou ménopausées. BéNéFICES, RISQUES ET COûTS: La population cible bénéficiera des plus récentes données scientifiques publiées que leur communiqueront les fournisseurs de soins de santé.

Guideline No. 422f: Menopause and Breast Cancer.

Objective: Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence.

Target Population: Perimenopausal and postmenopausal women.

Benefits, Harms, And Costs: Target population will benefit from the most recent published scientific evidence provided via the information from their health care provider.

Directive clinique n 422e : Ménopause et maladies cardiovasculaires.

Objectif: Proposer des stratégies pour améliorer les soins aux femmes en périménopause ou ménopausées d'après les plus récentes données probantes publiées.

Population Cible: Femmes en périménopause ou ménopausées. BéNéFICES, RISQUES ET COûTS: La population cible bénéficiera des plus récentes données scientifiques publiées que leur communiqueront les fournisseurs de soins de santé.

Guideline No. 422e: Menopause and Cardiovascular Disease.

Objective: Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence.

Target Population: Perimenopausal and postmenopausal women.

Benefits, Harms, And Costs: Target population will benefit from the most recent published scientific evidence provided via the information from their health care provider.

Guideline No. 422c: Menopause: Mood, Sleep, and Cognition.

Objective: Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence.

Target Population: Perimenopausal and postmenopausal women.

Benefits, Harms, And Costs: Target population will benefit from the most recent published scientific evidence provided via the information from their health care provider.

Directive clinique n 422a : Ménopause : symptômes vasomoteurs, agents thérapeutiques d'ordonnance, médecines douces et complémentaires, nutrition et mode de vie.

Objectif: Proposer des stratégies pour améliorer les soins aux femmes ménopausées ou en périménopause d'après les plus récentes données probantes publiées.

Population Cible: Femmes ménopausées ou en périménopause. BéNéFICES, RISQUES ET COûTS: La population cible bénéficiera des plus récentes données scientifiques publiées que leur communiqueront les fournisseurs de soins de santé.

Directive clinique n 422b : Ménopause et santé génito-urinaire.

Objectif: Proposer des stratégies fondées sur les plus récentes données publiées pour améliorer les soins aux femmes ménopausées ou en périménopause.

Population Cible: Les femmes ménopausées ou en périménopause. BéNéFICES, RISQUES ET COûTS: La population cible bénéficiera des plus récentes données scientifiques publiées communiquées par leurs fournisseurs de soins de santé.

Directive clinique n° 422c : Ménopause : Humeur, sommeil et cognition.

Objectif: Proposer des stratégies fondées sur les plus récentes données publiées pour améliorer les soins aux femmes ménopausées ou en périménopause.

Population Cible: Les femmes ménopausées ou en périménopause. BéNéFICES, RISQUES ET COûTS: La population cible bénéficiera des plus récentes données scientifiques publiées communiquées par leurs fournisseurs de soins de santé.

Guideline No. 422d: Menopause and Sexuality.

Objective: Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence.

Target Population: Perimenopausal and postmenopausal women.

Benefits, Harms, And Costs: Target population will benefit from the most recent published scientific evidence provided via the information from their health care provider.

Guideline No. 422b: Menopause and Genitourinary Health.

Objective: Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence.

Target Population: Perimenopausal and postmenopausal women.

Benefits, Harms, And Costs: Target population will benefit from the most recent published scientific evidence provided via the information from their health care provider.

Guideline No. 422a: Menopause: Vasomotor Symptoms, Prescription Therapeutic Agents, Complementary and Alternative Medicine, Nutrition, and Lifestyle.

Objective: Provide strategies for improving the care of perimenopausal and postmenopausal women based on the most recent published evidence.

Target Population: Perimenopausal and postmenopausal women.

Benefits, Harms, And Costs: Target population will benefit from the most recent published scientific evidence provided via the information from their health care provider.

Treatment of Secondary Vestibulodynia with Conjugated Estrogen Cream: A Pilot, Double-Blind, Randomized Placebo-Controlled Trial.

Objective: To assess the efficacy of conjugated equine estrogen cream in reducing dyspareunia associated with secondary provoked vestibulodynia.

Methods: We conducted a randomized, double-blind, placebo-controlled trial that included women with secondary provoked vestibulodynia. Participants were randomly allocated to daily application of conjugated equine estrogen cream on the vulvar vestibule (estrogen group) or daily application of a similar placebo cream (placebo group).

Ostéoporose pendant la ménopause.

Objectif: Offrir aux fournisseurs de soins de santé des lignes directrices quant à la prévention, au diagnostic et à la prise en charge clinique de l'ostéoporose postménopausique.

Issues: Stratégies visant à identifier et à évaluer les femmes exposées à des risques élevés; utilisation de la densité minérale osseuse et des marqueurs du renouvellement des cellules osseuses pour l'évaluation du diagnostic et de la réaction à la prise en charge; et recommandations quant à la nutrition, à l'activité physique et au choix du traitement pharmacologique en vue de prévenir l'ostéoporose et d'en assurer la prise en charge. RéSULTATS: La littérature publiée a été récupérée par l'intermédiaire de recherches menées dans MEDLINE et The Cochrane Library le 30 août et le 18 septembre 2012, respectivement, au moyen d'un vocabulaire contrôlé (p.

Role of Dicer1-Dependent Factors in the Paracrine Regulation of Epididymal Gene Expression.

Dicer1 is an endoribonuclease involved in the biogenesis of functional molecules such as microRNAs (miRNAs) and endogenous small interfering RNAs (endo-siRNAs). These small non-coding RNAs are important regulators of post-transcriptional gene expression and participate in the control of male fertility. With the knowledge that 1) Dicer1-dependent factors are required for proper sperm maturation in the epididymis, and that 2) miRNAs are potent mediators of intercellular communication in most biological systems, we investigated the role of Dicer1-dependent factors produced by the proximal epididymis (initial segment/caput)- including miRNAs- on the regulation of epididymal gene expression in the distal epididymis regions (i.

Expression of genes related to prostaglandin synthesis or signaling in human subcutaneous and omental adipose tissue: depot differences and modulation by adipogenesis.

Objectives: (1) To examine depot-specific PGE2 and PGF2α release and mRNA expression of enzymes or receptors involved in PG synthesis or signaling in human adipose tissues; (2) to identify changes in expression of these transcripts through preadipocyte differentiation; and (3) to examine associations between adipose tissue mRNA expression of these transcripts and adiposity measurements.

Methods: Fat samples were obtained surgically in women. PGE2 and PGF2α release by preadipocytes and adipose tissue explants was measured.

RETIRED: Osteoporosis in menopause.

This document has been archived because it contains outdated information. It should not be consulted for clinical use, but for historical research only. Please visit the journal website for the most recent guidelines.

Expression of the prostaglandin F synthase AKR1B1 and the prostaglandin transporter SLCO2A1 in human fetal membranes in relation to spontaneous term and preterm labor.

Background: Human labor is a complex series of cellular and molecular events that occur at the materno-fetal and uterine levels. Many hypotheses have been proposed for the initiation of human labor, one hypothesis suggests that maturation of the fetus releases a signal in the amniotic fluid that will be transmitted to myometrium via the fetal membranes and initiate uterine contractions. There is strong evidence that prostaglandins (PGs) play a central role in initiation and progression of human labor.

Prostaglandin pathway gene expression in human placenta, amnion and choriodecidua is differentially affected by preterm and term labour and by uterine inflammation.

Background: Elucidation of the biochemical pathways involved in activation of preterm and term human labour would facilitate the development of effective management and inform judgements regarding the necessity for preterm tocolysis and post-term induction. Prostaglandins act at all stages of human reproduction, and are potentially activators of labour.

Methods: Expression of 15 genes involved in prostaglandin synthesis, transport and degradation was measured by qPCR using tissue samples from human placenta, amnion and choriodecidua at preterm and full-term vaginal and caesarean delivery.

Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women.

Introduction: We have previously observed that intravaginal prasterone (dehydroepiandrosterone, DHEA) improved all domains of female sexual dysfunction (FSD).

Aim: Investigate the influence of moderate/severe pain at sexual activity (dyspareunia) (MSD) at baseline on FSD following prasterone administration.

Methods: The effect of daily administration of prasterone (0, 3.